Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis

Bongani M Mayosi, Mpiko Ntsekhe, Jackie Bosch, Shaheen Pandie, Hyejung Jung, Freedom Gumedze, Janice Pogue, Lehana Thabane, Marek Smieja, Veronica Francis, Laura Joldersma, Kandithalal M Thomas, Baby Thomas, Abolade A Awotedu, Nombulelo P Magula, Datshana P Naidoo, Albertino Damasceno, Alfred Chitsa Banda, Basil Brown, Pravin Manga, Bruce Kirenga, Charles Mondo, Phindile Mntla, Jacob M Tsitsi, Ferande Peters, Mohammed R Essop, James B W Russell, James Hakim, Jonathan Matenga, Ayub F Barasa, Mahmoud U Sani, Taiwo Olunuga, Okechukwu Ogah, Victor Ansa, Akinyemi Aje, Solomon Danbauchi, Dike Ojji, Salim Yusuf, IMPI Trial Investigators, O Ajayi, M Badri, M Chhiba, C Chishala, C Cupido, A Deffur, M M De Vries Basson, P Mangena, K Moeketsi, M Mubanga, P Namale, P Raubenheimer, J Shenje, N Schreuder, Y Vallie, N van der Schyff, N Alam, F Khan, P Mkoko, A Mutyaba, M Valavi, V Bayi, N Duze, U Lalloo, T C Manzini, M R Matshela, K Sliwa-Hahnle, P Ntuli, N L Nqeketo, M J Mphahlele, L Ntyintyane, R Ramjee, N Tsabedze, Catarina Muinga, K Dembo, K Chipanda, J Mipungwi, A Adebiyi, N A Ishaq, M S Mijinyawa, B O Aina, A Ariyo, I Odudu-Umoh, C Akpan, M S Isa, A Oyati, S Conteh, A Serry-Bangura, N T Munyandu, T G Fana, D B Kiggundu, R Yanoh, B M Mayosi, M Ntsekhe, J Bosch, S Pandie, V Francis, M Smieja, S K Sharma, L Thabane, T Gasperini, S Yusuf, G Meintjes, P J Commerford, H Esmail, A Horak, J Nachega, T Oni, S Pandie, T Pillay, K Rebe, R Scott Millar, K Sliwa-Hahnle, V Francis, F Gili, C Hunsinger Lemmer, L Mhlanti, S Nkepu, J Saaiman, U September, R Vergotine, M Van de Wall, J Bosch, A Abdallah, S Hall, L Joldersma, H Jung, M Kuofie, J Miller, J Pogue, S Pandie, C Gibbon, N Killa, L Petersen, F Walker, H Abercrombie, N Rossi, X Sengoatse, W Grootboom, N P Mdlatu, N Ndinisa, Y Kriel, N Lushozi, N Mkhize, G Ntonga, R Pillay, P Gumede, P Methusi, L K Rikhotso, T Tau, V Paton, K Robertson, G Muchanga, R Chigona, W T Kaneka, M Malahleka, J Mwantani, A Odidi, K Conteh, E Dzvinyayi, I Gudza, P Manuhwa, V G Masore, S Mudzinswa, R Bujungu, S Mugambe, R M Jepkokir, S W Njuguna, F Gumedze, J Pogue, H Jung, P Gao, D Sackett, C Lombard, J Moodley, H Reuter, J Volmink, Bongani M Mayosi, Mpiko Ntsekhe, Jackie Bosch, Shaheen Pandie, Hyejung Jung, Freedom Gumedze, Janice Pogue, Lehana Thabane, Marek Smieja, Veronica Francis, Laura Joldersma, Kandithalal M Thomas, Baby Thomas, Abolade A Awotedu, Nombulelo P Magula, Datshana P Naidoo, Albertino Damasceno, Alfred Chitsa Banda, Basil Brown, Pravin Manga, Bruce Kirenga, Charles Mondo, Phindile Mntla, Jacob M Tsitsi, Ferande Peters, Mohammed R Essop, James B W Russell, James Hakim, Jonathan Matenga, Ayub F Barasa, Mahmoud U Sani, Taiwo Olunuga, Okechukwu Ogah, Victor Ansa, Akinyemi Aje, Solomon Danbauchi, Dike Ojji, Salim Yusuf, IMPI Trial Investigators, O Ajayi, M Badri, M Chhiba, C Chishala, C Cupido, A Deffur, M M De Vries Basson, P Mangena, K Moeketsi, M Mubanga, P Namale, P Raubenheimer, J Shenje, N Schreuder, Y Vallie, N van der Schyff, N Alam, F Khan, P Mkoko, A Mutyaba, M Valavi, V Bayi, N Duze, U Lalloo, T C Manzini, M R Matshela, K Sliwa-Hahnle, P Ntuli, N L Nqeketo, M J Mphahlele, L Ntyintyane, R Ramjee, N Tsabedze, Catarina Muinga, K Dembo, K Chipanda, J Mipungwi, A Adebiyi, N A Ishaq, M S Mijinyawa, B O Aina, A Ariyo, I Odudu-Umoh, C Akpan, M S Isa, A Oyati, S Conteh, A Serry-Bangura, N T Munyandu, T G Fana, D B Kiggundu, R Yanoh, B M Mayosi, M Ntsekhe, J Bosch, S Pandie, V Francis, M Smieja, S K Sharma, L Thabane, T Gasperini, S Yusuf, G Meintjes, P J Commerford, H Esmail, A Horak, J Nachega, T Oni, S Pandie, T Pillay, K Rebe, R Scott Millar, K Sliwa-Hahnle, V Francis, F Gili, C Hunsinger Lemmer, L Mhlanti, S Nkepu, J Saaiman, U September, R Vergotine, M Van de Wall, J Bosch, A Abdallah, S Hall, L Joldersma, H Jung, M Kuofie, J Miller, J Pogue, S Pandie, C Gibbon, N Killa, L Petersen, F Walker, H Abercrombie, N Rossi, X Sengoatse, W Grootboom, N P Mdlatu, N Ndinisa, Y Kriel, N Lushozi, N Mkhize, G Ntonga, R Pillay, P Gumede, P Methusi, L K Rikhotso, T Tau, V Paton, K Robertson, G Muchanga, R Chigona, W T Kaneka, M Malahleka, J Mwantani, A Odidi, K Conteh, E Dzvinyayi, I Gudza, P Manuhwa, V G Masore, S Mudzinswa, R Bujungu, S Mugambe, R M Jepkokir, S W Njuguna, F Gumedze, J Pogue, H Jung, P Gao, D Sackett, C Lombard, J Moodley, H Reuter, J Volmink

Abstract

Background: Tuberculous pericarditis is associated with high morbidity and mortality even if antituberculosis therapy is administered. We evaluated the effects of adjunctive glucocorticoid therapy and Mycobacterium indicus pranii immunotherapy in patients with tuberculous pericarditis.

Methods: Using a 2-by-2 factorial design, we randomly assigned 1400 adults with definite or probable tuberculous pericarditis to either prednisolone or placebo for 6 weeks and to either M. indicus pranii or placebo, administered in five injections over the course of 3 months. Two thirds of the participants had concomitant human immunodeficiency virus (HIV) infection. The primary efficacy outcome was a composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis.

Results: There was no significant difference in the primary outcome between patients who received prednisolone and those who received placebo (23.8% and 24.5%, respectively; hazard ratio, 0.95; 95% confidence interval [CI], 0.77 to 1.18; P=0.66) or between those who received M. indicus pranii immunotherapy and those who received placebo (25.0% and 24.3%, respectively; hazard ratio, 1.03; 95% CI, 0.82 to 1.29; P=0.81). Prednisolone therapy, as compared with placebo, was associated with significant reductions in the incidence of constrictive pericarditis (4.4% vs. 7.8%; hazard ratio, 0.56; 95% CI, 0.36 to 0.87; P=0.009) and hospitalization (20.7% vs. 25.2%; hazard ratio, 0.79; 95% CI, 0.63 to 0.99; P=0.04). Both prednisolone and M. indicus pranii, each as compared with placebo, were associated with a significant increase in the incidence of cancer (1.8% vs. 0.6%; hazard ratio, 3.27; 95% CI, 1.07 to 10.03; P=0.03, and 1.8% vs. 0.5%; hazard ratio, 3.69; 95% CI, 1.03 to 13.24; P=0.03, respectively), owing mainly to an increase in HIV-associated cancer.

Conclusions: In patients with tuberculous pericarditis, neither prednisolone nor M. indicus pranii had a significant effect on the composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis. (Funded by the Canadian Institutes of Health Research and others; IMPI ClinicalTrials.gov number, NCT00810849.).

Figures

Figure 1. Kaplan–Meier Estimates of the Time…
Figure 1. Kaplan–Meier Estimates of the Time to the Primary Efficacy Outcome, According to Treatment Group
Data on the time to the primary efficacy outcome of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis are shown for patients who received prednisolone or placebo (Panel A) and Mycobacterium indicus pranii or placebo (Panel B).
Figure 2. Time to Cancer Occurrence
Figure 2. Time to Cancer Occurrence
Shown are Kaplan–Meier estimates of the time to cancer occurrence for all four comparisons in the 2-by-2 factorial trial. The inset shows the same data on an enlarged y axis.

Source: PubMed

3
Subscribe